• Publications
  • Influence
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
TLDR
High-dose antithrombin III therapy had no effect on 28-day all-cause mortality in adult patients with severe sepsis and septic shock when administered within 6 hours after the onset.
High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial
TLDR
High-dose antithrombin III therapy had no effect on 28-day all-cause mortality in adult patients with severe sepsis and septic shock when administered within 6 hours after the onset and was associated with an increased risk of hemorrhage when administered with heparin.
Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial
TLDR
PCC treatment serves as an effective rapid hemorrhage control resource in the emergency anticoagulant reversal setting and more widespread availability of PCC is warranted to ensure its benefits in appropriate patients.
Antithrombin, heparin, and heparan sulfate
TLDR
The results of a recent phase 3 clinical trials with high-dose antithrombin in sepsis suggested a beneficial effect in patients who did not concomitantly receive heparin, thereby generating new challenges in the understanding of interactions between antithromabin and heparIn or hepar in-like proteoglycans.
Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
TLDR
Rapid PCC infusion produced prompt sustained increases in coagulation factors and anticoagulant proteins with no clinical evidence of thrombosis or viral transmission.
Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia
TLDR
Hemparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, and fondaparinux as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A
Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults.
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction
Development of neutralizing inhibitors against factor VIII (FVIII) is a major complication of haemophilia A treatment.
The first recombinant FVIII produced in human cells – an update on its clinical development programme
TLDR
Human‐cl rhFVIII is efficacious and safe in the prevention and treatment of bleeding episodes and that none of the treated patients developed inhibitors or allergic reactions thus far, and pharmacokinetic data with a mean half‐life of 17.1 h allow personalized prophylaxis with the chance of fewer infusions.
Pharmacokinetics and safety of fibrinogen concentrate
TLDR
The results support the idea that FCH substitution can restore hemostasis with a good safety profile, and confirm a rapid increase in plasma fibrinogen levels after infusion with FCH.
...
1
2
3
4
5
...